. 2018 Dec 12;24(2):123–130. doi: 10.1007/s10147-018-1378-0

Table 1.

Comprehensive cancer panel sequencing tests for implementation in Japan

Comprehensive cancer panel sequencing tests	Target			Approval
Comprehensive cancer panel sequencing tests	DNA	RNA	Fusion	Approval
Oncomine™ Dx Target Test CDx system	1 (46)^a	(46)^a		Authorized by PMDA as a CDx for BRAF V600E ^b
NCC OncoPanel	114		13	The Japanese Advanced Medical Care B program
Todai OncoPanel	465	467	17	The Japanese Advanced Medical Care B program
Oncomine™ Target Test	46	46		The Japanese Advanced Medical Care B program
OncoPrime	223			Research
MSK-IMPACT	468		18	Research
PleSSision	160			Research
Guardant360	73			Research
CANCERPLEX	435			research
ACTOnco+	440			Research
FoundationOne CDx™	324			Research (authorized by FDA as a CDx^c)
Oncomine™ Dx Target Test	23 (46)^a	23 (46)^a		Research (authorized by FDA as a CDx^d)
MSK-IMPACT	468		18	Research (authorized by FDA as an IVD^e)

^aOncomine Dx target test and Oncomine Dx target test CDx system potentially detect alterations in 46 genes